Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
Understanding the role of cardiac macrophages in the recovery of heart failure
FY 2020-21
Summary
Heart failure (HF) arises after an injury to the heart causes it to pump less effectively. There are about 23 million HF cases worldwide, ~660,000 of which are in Canada, with the number steadily increasing. Standard HF therapies enhance heart pumping and improve clinical outcomes. Although patients initially stabilize on these therapies, recent studies show that HF recurs after this initial phase. Why some become stable (termed "remission") and why some "relapse" and have recurrent HF despite having optimal therapy is unknown, but represents a significant unmet clinical need. To begin to address this problem, a clinically relevant mouse model of HF recovery was developed. Importantly, HF redevelops in these mice when stressed a second time. A striking observation from this model is that the level of inflammation in HF-recovered hearts is the same as in failing hearts, raising the possibility that persistent inflammation may contribute to relapsing HF. The proposed work examines the role of immune cells called macrophages in HF recovery, as they are primary mediators of tissue repair and inflammation in the heart. The healthy heart typically harbors two macrophage types: one population that everyone is born with (embryonic) and is responsible for tissue repair, and one derived when blood cells from the bone marrow enter the heart after tissue injury, which is inherently more inflammatory. In this work, the applicant will first examine how these macrophage populations are affected in the course of HF recovery using the HF recovery mouse model. Using genetic methods, the applicant will then selectively alter the abundance of each macrophage population when the hearts are stressed a second time. These studies will allow us to determine the contributions of each macrophage group to the stability of HF recovery, and relapse. Results from this work may lead to new therapies that help lengthen the time HF patients remain in remission, free from costly hospital admissions.
Department
Program
Banting Postdoctoral Fellowship Program
Recipient
Location
Missouri, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
436277
Name
Lim Kenji Rowel Q
Region
Missouri
Country
United States of America
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Understanding the role of cardiac macrophages in the recovery of heart failure
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Cardiac Macrophages; Conditional Knockout Mice; Genetic Manipulation; Heart Failure; Heart Failure Recovery; Heart Failure Remission; Heart Failure With Reduced Ejection Fraction; Inflammation; Neurohormonal/Hemodynamic Stress; Single-Cell Rna Sequencing
Abstract
Heart failure (HF) arises after an injury to the heart causes it to pump less effectively. There are about 23 million HF cases worldwide, ~660,000 of which are in Canada, with the number steadily increasing. Standard HF therapies enhance heart pumping and improve clinical outcomes. Although patients initially stabilize on these therapies, recent studies show that HF recurs after this initial phase. Why some become stable (termed "remission") and why some "relapse" and have recurrent HF despite having optimal therapy is unknown, but represents a significant unmet clinical need. To begin to address this problem, a clinically relevant mouse model of HF recovery was developed. Importantly, HF redevelops in these mice when stressed a second time. A striking observation from this model is that the level of inflammation in HF-recovered hearts is the same as in failing hearts, raising the possibility that persistent inflammation may contribute to relapsing HF. The proposed work examines the role of immune cells called macrophages in HF recovery, as they are primary mediators of tissue repair and inflammation in the heart. The healthy heart typically harbors two macrophage types: one population that everyone is born with (embryonic) and is responsible for tissue repair, and one derived when blood cells from the bone marrow enter the heart after tissue injury, which is inherently more inflammatory. In this work, the applicant will first examine how these macrophage populations are affected in the course of HF recovery using the HF recovery mouse model. Using genetic methods, the applicant will then selectively alter the abundance of each macrophage population when the hearts are stressed a second time. These studies will allow us to determine the contributions of each macrophage group to the stability of HF recovery, and relapse. Results from this work may lead to new therapies that help lengthen the time HF patients remain in remission, free from costly hospital admissions.
Competitiondate
202010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Lim, Kenji Rowel Q
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~